Background:
Hypertension remains a major therapeutic challenge with significant morbidity, requiring novel pharmacological options. Selective aldosterone synthase inhibitors (ASIs), particularly baxdrostat and lorundrostat, offer a potent approach to blood pressure control. However, their comparative renal safety pr...
Hamza Sajid, Hamdia Gul Aslam, Sarah Zaka et al.· Circulation· 0 citations
Background:
Hypertension, particularly resistant hypertension, persists as a major global burden associated with significant challenges in therapeutic management. Baxdrostat, a selective aldosterone synthase inhibitor, can be investigated as a potential therapy for blood pressure treatment. We conducted a meta-analy...
Hamza Sajid, K. M. Hassan, Hamdia Gul Aslam et al.· Circulation· 0 citations
Background:
Dyslipidemia is a major contributor to cardiovascular morbidity and mortality, making optimized statin therapy essential for lipid management. Although pitavastatin has demonstrated favorable effects on lipid parameters and tolerability, its dose-dependent efficacy and safety compared with commonly presc...
Hamza Sajid, Hassan E. Muhammad, C. Sohail et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.